Skip to content
Inciteful Med

Treatment Strategy: Protecting Your Lungs and Liver

Last updated:

Managing Alpha-1 antitrypsin deficiency (AATD) requires a dual approach: protecting the lungs through augmentation therapy, inhalers, and smoking cessation, while monitoring the liver for scarring. Avoiding lung irritants and eliminating alcohol are essential to slow disease progression.

Key Takeaways

  • • Augmentation therapy involves weekly IV infusions to increase protective lung proteins and slow lung damage.
  • • Quitting smoking is mandatory to prevent rapid acceleration of AATD-related lung disease.
  • • Liver care focuses on monitoring with tests like FibroScan and strictly avoiding alcohol to prevent liver scarring.
  • • New investigational RNA therapies are currently being studied to target and reduce toxic protein clumps in the liver.

Managing Alpha-1 Antitrypsin Deficiency (AATD) requires a dual approach: replacing the protective protein your lungs are missing and monitoring the liver for signs of stress or damage [1][2]. While there is currently no “cure” that changes your genetics, modern treatments and lifestyle changes can significantly slow the progression of the disease and improve your quality of life [3][4].

Protecting Your Lungs

The goal of lung treatment is to restore the balance between protective proteins and destructive enzymes [5][6].

Daily Symptom Management

Before considering specialized therapies, it is crucial to manage everyday breathing symptoms, much like standard COPD:

  • Inhalers and Bronchodilators: Medications that open your airways and reduce inflammation are often the first line of defense to help you breathe easier on a daily basis [7].
  • Pulmonary Rehabilitation: Structured exercise and education programs specifically designed for people with lung disease can significantly improve your exercise tolerance and quality of life [8].
  • Infection Prevention: Catching a cold or pneumonia is dangerous for someone with compromised lungs. Regular handwashing, avoiding sick individuals, wearing a mask in crowded areas, and staying up-to-date on vaccines (flu, pneumonia, COVID-19) are vital daily habits [9].

Augmentation Therapy

The specific treatment for AATD-related lung disease is augmentation therapy [10][9]. This involves a weekly intravenous (IV) infusion of purified alpha-1 antitrypsin protein collected from healthy donors [11][12].

  • Who is it for? It is typically recommended for non-smokers or former smokers (you must stop smoking entirely to qualify) with severe AATD who have already begun to show signs of lung disease, often defined by a lung function measurement (FEV1) between 30% and 65% of what is predicted for their age [13][14].
  • What does it do? It raises the level of protective protein in your blood and lungs [11]. While it may not significantly change how you feel day-to-day, it has been proven to slow the loss of lung tissue (density) as seen on specialized CT scans [15][5][16].
  • Important Caveat: Augmentation therapy only protects the lungs. It does not treat, prevent, or reverse AATD-related liver damage [17].

Essential Lifestyle Changes

The single most powerful “treatment” for your lungs is avoiding irritants.

  • Smoking Cessation: Smoking is the fastest way to accelerate lung damage in someone with AATD [18][19]. Stopping smoking is mandatory for anyone diagnosed with this condition [19].
  • Environmental Protection: Avoid exposure to secondhand smoke, heavy dust, or industrial chemicals at work, as these also trigger the inflammatory enzymes that damage the lungs [20][18].

Protecting Your Liver

Because liver disease in AATD is caused by “clumping” of proteins inside the liver cells, the treatment strategy is different from the lungs [21][22].

Monitoring and Standard Care

Currently, there is no approved medication to “un-clump” these proteins, so care focuses on monitoring and prevention:

  • Regular Screening: Doctors use non-invasive tests like FibroScan (a specialized ultrasound that measures liver stiffness) and blood tests for liver enzymes to check for scarring (fibrosis) [23][7].
  • Alcohol Avoidance: Alcohol places extra stress on liver cells that are already struggling. Reducing or eliminating alcohol is highly recommended to prevent further damage [23][24].
  • Liver Transplant: For life-threatening liver failure or cirrhosis, a liver transplant is a highly effective treatment that also “cures” the deficiency, as the new liver will produce normal AAT protein [25][26].

The Future: Investigational Therapies

New treatments are being studied that specifically target the liver’s “toxic gain-of-function.” One promising approach uses RNA interference (RNAi), such as an experimental drug called Fazirsiran [27][28]. These therapies work by “turning off” the production of the abnormal protein in the liver, which has shown promise in reducing protein clumps and improving liver health in early clinical trials [27][28][29].

Frequently Asked Questions

What is augmentation therapy for AATD?
Augmentation therapy is a weekly intravenous infusion of purified alpha-1 antitrypsin protein. It helps raise protective protein levels in the blood and lungs to slow lung tissue damage in eligible patients.
Does augmentation therapy help with AATD liver damage?
No, augmentation therapy only protects the lungs. It does not treat, prevent, or reverse liver damage caused by Alpha-1 antitrypsin deficiency.
How is liver disease monitored in AATD?
Doctors monitor liver health using non-invasive tests like FibroScan, which measures liver stiffness using specialized ultrasound, alongside routine blood tests to check liver enzyme levels.
Can lifestyle changes improve AATD symptoms?
Yes. Stopping smoking is the most critical step to protect your lungs, while reducing or eliminating alcohol helps prevent further stress and damage to your liver.
Are there new treatments for AATD liver disease?
Researchers are studying investigational therapies like RNA interference (RNAi) drugs, such as Fazirsiran. These aim to stop the production of abnormal proteins in the liver to reduce toxic buildup and liver damage.

Questions for Your Doctor

  • • What is my current FEV1 percentage, and how does it affect my daily treatment options?
  • • Based on my FEV1 and lung density results, am I a candidate for starting augmentation therapy now?
  • • Am I eligible for a pulmonary rehabilitation program in our area?
  • • Can you check my liver for fibrosis (scarring) using a non-invasive test like a FibroScan or ultrasound?
  • • Are there any clinical trials for 'liver-directed' treatments like Fazirsiran that I might be eligible for?

Questions for You

  • • Am I still smoking, or am I exposed to secondhand smoke or heavy dust at work? (Addressing these is the most critical step you can take for your lungs).
  • • How much alcohol do I consume? (Reducing or eliminating alcohol is vital for protecting your liver if you have AATD).
  • • Do I have a support system in place to help me manage weekly infusions if I start augmentation therapy?
  • • Have I noticed any new symptoms, like swelling in my legs or yellowing of my skin (jaundice), that I should report to my doctor?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Known Mutations at the Cause of Alpha-1 Antitrypsin Deficiency an Updated Overview of SERPINA1 Variation Spectrum.

    Seixas S, Marques PI

    The application of clinical genetics 2021; (14()):173-194 doi:10.2147/TACG.S257511.

    PMID: 33790624
  2. 2

    The Role of Neutrophils in Alpha-1 Antitrypsin Deficiency.

    McCarthy C, Reeves EP, McElvaney NG

    Annals of the American Thoracic Society 2016; (13 Suppl 4()):S297-304 doi:10.1513/AnnalsATS.201509-634KV.

    PMID: 27564664
  3. 3

    Alpha-1 antitrypsin deficiency: outstanding questions and future directions.

    Torres-Durán M, Lopez-Campos JL, Barrecheguren M, et al.

    Orphanet journal of rare diseases 2018; (13(1)):114 doi:10.1186/s13023-018-0856-9.

    PMID: 29996870
  4. 4

    Alpha-1 antitripsyn deficiency and augmentation therapy in pregnancy: two case reports.

    Annunziata A, Fiorentino G, Coppola A, et al.

    Frontiers in medicine 2024; (11()):1479877 doi:10.3389/fmed.2024.1479877.

    PMID: 39736979
  5. 5

    Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.

    Rahaghi FF, Miravitlles M

    Respiratory research 2017; (18(1)):105 doi:10.1186/s12931-017-0574-1.

    PMID: 28558837
  6. 6

    The Role of Computed Tomography for the Evaluation of Lung Disease in Alpha-1 Antitrypsin Deficiency.

    Campos MA, Diaz AA

    Chest 2018; (153(5)):1240-1248 doi:10.1016/j.chest.2017.11.017.

    PMID: 29175361
  7. 7

    [Alpha 1-antitrypsin deficiency].

    Mornex JF

    Revue des maladies respiratoires 2022; (39(8)):698-707 doi:10.1016/j.rmr.2022.02.062.

    PMID: 35715315
  8. 8

    Alpha 1-antitrypsin deficiency in patients with chronic obstructive pulmonary disease patients: is systematic screening necessary?

    da Costa CH, Noronha Filho AJ, Marques E Silva RMF, et al.

    BMC research notes 2019; (12(1)):10 doi:10.1186/s13104-018-4043-9.

    PMID: 30630519
  9. 9

    The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult.

    Sandhaus RA, Turino G, Brantly ML, et al.

    Chronic obstructive pulmonary diseases (Miami, Fla.) 2016; (3(3)):668-682 doi:10.15326/jcopdf.3.3.2015.0182.

    PMID: 28848891
  10. 10

    Management of lung disease in alpha-1 antitrypsin deficiency: what we do and what we do not know.

    Barjaktarevic I, Campos M

    Therapeutic advances in chronic disease 2021; (12_suppl()):20406223211010172 doi:10.1177/20406223211010172.

    PMID: 34408831
  11. 11

    [Longterm Homecare Augmentation Program in Alpha-1-Antitrypsin Deficient Patients].

    Wilke A, Semper H, Gross C, Grohé C

    Pneumologie (Stuttgart, Germany) 2018; (72(8)):590-597 doi:10.1055/a-0618-7493.

    PMID: 30089330
  12. 12

    Case report: Self-administration of alpha-1 antitrypsin therapy: a report of two cases.

    Escribano Dueñas AM, Martín García M, Tortajada Goitia B, Arenas Villafranca JJ

    Frontiers in pharmacology 2023; (14()):1291677 doi:10.3389/fphar.2023.1291677.

    PMID: 38074132
  13. 13

    Alpha-1 antitrypsin deficiency in the elderly: a case report.

    Annunziata A, Lanza M, Coppola A, Fiorentino G

    Journal of medical case reports 2021; (15(1)):231 doi:10.1186/s13256-021-02847-w.

    PMID: 33966640
  14. 14

    Alpha-1-Antitrypsin Deficiency: Disease Management and Learning from Studies.

    Greulich T

    COPD 2017; (14(sup1)):S8-S11 doi:10.1080/15412555.2017.1286166.

    PMID: 28306355
  15. 15

    Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications.

    Chapman KR, Chorostowska-Wynimko J, Koczulla AR, et al.

    International journal of chronic obstructive pulmonary disease 2018; (13()):419-432 doi:10.2147/COPD.S149429.

    PMID: 29430176
  16. 16

    Randomized, Placebo-Controlled Trials in Alpha-1 Antitrypsin Deficiency.

    Sandhaus RA

    Annals of the American Thoracic Society 2016; (13 Suppl 4()):S370-3 doi:10.1513/AnnalsATS.201510-684KV.

    PMID: 27564674
  17. 17

    Obstacles to Early Diagnosis and Treatment of Alpha-1 Antitrypsin Deficiency: Current Perspectives.

    Quinn M, Ellis P, Pye A, Turner AM

    Therapeutics and clinical risk management 2020; (16()):1243-1255 doi:10.2147/TCRM.S234377.

    PMID: 33364772
  18. 18

    Pulmonary manifestations of alpha 1 antitrypsin deficiency.

    Mulkareddy V, Roman J

    The American journal of the medical sciences 2024; (368(1)):1-8 doi:10.1016/j.amjms.2024.04.002.

    PMID: 38599244
  19. 19

    Recurrence of emphysema post-lung transplantation in a patient with alpha 1 antitrypsin deficiency (AATD).

    Ataya A

    Respiratory medicine case reports 2020; (31()):101309 doi:10.1016/j.rmcr.2020.101309.

    PMID: 33304809
  20. 20

    Why is Disease Penetration so Variable in Alpha-1 Antitrypsin Deficiency? The Contribution of Environmental Factors.

    Rangaraju M, Turner AM

    Chronic obstructive pulmonary diseases (Miami, Fla.) 2020; (7(3)):280-289 doi:10.15326/jcopdf.7.3.2019.0177.

    PMID: 32698254
  21. 21

    Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort.

    Clark VC, Marek G, Liu C, et al.

    Journal of hepatology 2018; (69(6)):1357-1364 doi:10.1016/j.jhep.2018.08.005.

    PMID: 30138687
  22. 22

    SVIP regulates Z variant alpha-1 antitrypsin retro-translocation by inhibiting ubiquitin ligase gp78.

    Khodayari N, Wang RL, Marek G, et al.

    PloS one 2017; (12(3)):e0172983 doi:10.1371/journal.pone.0172983.

    PMID: 28301499
  23. 23

    Future Perspectives in the Diagnosis and Treatment of Liver Disease Associated with Alpha-1 Antitrypsin Deficiency.

    Abreu N, Pereira VM, Pestana M, Jasmins L

    GE Portuguese journal of gastroenterology 2023; (30(5)):327-335 doi:10.1159/000528809.

    PMID: 37868641
  24. 24

    Alpha-1 Antitrypsin Deficiency: Principles of Care.

    Rodrigues JF, Mineiro A, Reis A, et al.

    Acta medica portuguesa 2020; (33(6)):433-439 doi:10.20344/amp.12950.

    PMID: 32504520
  25. 25

    Systematic review: the natural history of alpha-1 antitrypsin deficiency, and associated liver disease.

    Townsend SA, Edgar RG, Ellis PR, et al.

    Alimentary pharmacology & therapeutics 2018; (47(7)):877-885 doi:10.1111/apt.14537.

    PMID: 29446109
  26. 26

    Severe alpha-1 antitrypsin deficiency is associated with a higher risk of complications after first decompensation than other aetiologies of cirrhosis.

    Balcar L, Fromme M, Kappe N, et al.

    JHEP reports : innovation in hepatology 2025; (7(6)):101398 doi:10.1016/j.jhepr.2025.101398.

    PMID: 40535554
  27. 27

    Fazirsiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease findings from the SEQUOIA phase 2 trial.

    Liaquat T, Malik BT, Hashmi TH, et al.

    Annals of medicine and surgery (2012) 2025; (87(7)):4014-4016 doi:10.1097/MS9.0000000000003393.

    PMID: 40851970
  28. 28

    Cleaning up alpha-1 antitrypsin deficiency related liver disease.

    Rademacher L, Fromme M, Strnad P

    Current opinion in gastroenterology 2023; (39(3)):163-168 doi:10.1097/MOG.0000000000000919.

    PMID: 37144533
  29. 29

    Alpha-1 antitrypsin deficiency-associated liver disease: From understudied disorder to the poster child of genetic medicine.

    Fromme M, Klebingat F, Ellis P, Strnad P

    Hepatology communications 2025; (9(5)) doi:10.1097/HC9.0000000000000699.

    PMID: 40227077

This page provides educational information about AATD treatments and lifestyle management. Always consult your pulmonologist or hepatologist before making changes to your medical care plan.

Stay up to date

Get notified when new research about Alpha-1-antitrypsin deficiency is published.

No spam. Unsubscribe anytime.